Large gap with delayed quotes
|
Last quote
12/27/2024 -
17:20:00
|
Bid
12/27/2024 -
15:59:59
|
Bid Volume |
Ask
12/27/2024 -
15:59:59
|
Ask Volume |
|---|---|---|---|---|
|
89.40
-2.22
(
-2.42% )
|
89.41
|
400 |
89.48
|
100 |
Analysis date: 24.12.2024
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 26.11.2024.
Interest
Very weak
Very weak
Very weak interest since 20.12.2024.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 26.11.2024 at a price of 94.63.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, at its current price the stock is moderately undervalued.
MT Tech Trend
Negative
Negative
The forty day Medium Term Technical Trend is negative since 20.12.2024. The confirmed Technical Reverse point (Tech Reverse + 1.75%) is
4wk Rel Perf
-4.51%
-4.51%
The four week relative underperformance versus SP500 is 4.51%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 15.11.2024.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 0.88%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.54%.
Mkt Cap in $bn
5.74
5.74
With a market capitalization between $2 & $8bn, BLUEPRINT MEDICINES is considered a mid-cap stock.
G/PE Ratio
2.76
2.76
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
25.97
25.97
The estimated PE is for the year 2027.
LT Growth
71.77%
71.77%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
16
16
Over the last seven weeks, an average of 16 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
162
162
For 1% of index variation, the stock varies on average by 1.62%.
Correlation
0.42
0.42
41.96% of stock movements are explained by index variations.
Value at Risk
29.71
29.71
The value at risk is estimated at USD 29.71. The risk is therefore 32.84%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
17.04.2018
17.04.2018